A new role for cathodoluminescence spectroscopy and imaging as an analytical tool to support the development of pharmaceutical products

Cathodoluminescence (CL) analysis using a MonoCLTM system has recently been described as a technique for use with scanning electron microscopy to complement existing solid state spectroscopic and imaging tools that are used to support the understanding, development and manufacture of medicinal products.1,2 This may seem unremarkable to the many existing users of CL spectroscopy and imaging, but it is a significant and overdue advance in pharmaceutical research and development, and as a way to support and defend intellectual property.